Stock Markets February 12, 2026 10:28 AM

Crocs rallies 20% after management raises 2026 earnings outlook and posts Q4 beat

Stronger-than-expected EPS guidance for 2026, modest margin expansion and cost-savings targets underpin sharp stock move

By Priya Menon CROX

Crocs Inc. shares jumped roughly 20% after the company reported fourth-quarter results above analyst expectations and provided 2026 guidance that exceeded consensus. Management penciled in adjusted EPS between $12.88 and $13.35 for 2026, outlined a $100 million cost-savings target and signaled modest operating-margin expansion from fiscal 2025 levels.

Crocs rallies 20% after management raises 2026 earnings outlook and posts Q4 beat
CROX

Key Points

  • Crocs provided 2026 adjusted EPS guidance of $12.88 to $13.35, above analysts' $11.89 estimate - impacts consumer discretionary and retail sectors.
  • Company beat Q4 sales and profit expectations, led by international direct-to-consumer holiday demand for both Crocs and HEYDUDE - impacts footwear and e-commerce channels.
  • Management plans $100 million in cost savings by 2026 and expects adjusted operating margin to "expand modestly" from 22.3% in fiscal 2025 - relevant to corporate margin and supply-chain efficiency discussions.

Shares of Crocs Inc. (NASDAQ:CROX) climbed about 20% after the footwear maker released fourth-quarter results that topped estimates and issued a 2026 earnings outlook that surpassed analyst projections.


Guidance and consensus comparison

The company set 2026 adjusted earnings per share guidance in a range of $12.88 to $13.35, well above the $11.89 per-share consensus compiled by LSEG. For full-year 2026 revenue, management expects a range spanning a 1% decline to a marginal increase, versus analysts' projection for a 0.8% decline.

Quarterly performance and demand drivers

Crocs exceeded Wall Street expectations for both fourth-quarter sales and profits, a result the company attributed to strong holiday-season demand for its core styles within international direct-to-consumer channels. The company's primary brand and its HEYDUDE division both helped drive revenue higher than anticipated.

Cost savings and margin outlook

Chief Executive Andrew Rees said the firm will pursue $100 million in cost savings by 2026. In addition, management signaled that adjusted operating margin should "expand modestly" from the 22.3% reported in fiscal 2025.

Analyst perspective and valuation

Stifel highlighted the valuation implications of the guidance: "Valuation remains intriguing, with the pre-market price pointing to 7x P/E on FY26E adj. EPS guidance. Our $90 target price and Hold thesis presumes a level of tension between promotional intensity and revenue growth, and we will update our estimates after the call," Stifel wrote.

Based on the company's guidance, the current share price implies roughly 7 times projected 2026 earnings.


Market reaction

Investors reacted to the combination of a stronger-than-expected EPS outlook, cost-saving initiatives and a positive holiday-season sales cadence by bidding the stock materially higher in trading following the release.

Risks

  • Revenue guidance spans a range from a 1% decline to a marginal increase, indicating uncertainty around top-line growth - affects consumer discretionary and retail outlooks.
  • Stifel notes potential tension between promotional intensity and revenue growth, signaling a risk that discounting could pressure margins or sales mix - impacts retail pricing strategies and margin profiles.
  • Margin expansion is described as "modest," leaving limited visibility on the scale and timing of profit improvements - relevant to investor expectations for profitability recovery.

More from Stock Markets

Red Cat Holdings Sees After-Hours Slide Following $200 Million Equity Offering Announcement May 12, 2026 FCC Signs Off on EchoStar’s $40 Billion Spectrum Sale to SpaceX and AT&T May 12, 2026 CFPB Leadership Moving to Bring Staff Back to Office After Year-Long Closure May 12, 2026 AEP to Sell $2.6 Billion in Stock; Shares Slip After-Hours May 12, 2026 Mirum Pharmaceuticals Announces $600M Convertible Bond Sale; Shares Slip in After-Hours Trading May 12, 2026